Open AccessCan Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
Author(s) -
Sicheng Zhou,
Qiang Feng,
Jing Zhang,
Haitao Zhou,
Zheng Jiang,
Jianwei Liang,
Wei Pei,
Qian Liu,
Zhixiang Zhou,
Xishan Wang
Publication year - 2021
Publication title -
clinical interventions in aging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 76
eISSN - 1178-1998
pISSN - 1176-9092
DOI - 10.2147/cia.s293412
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , cytoreductive surgery , chemotherapy , intraperitoneal chemotherapy , metastasis , oncology , surgery , general surgery , cancer , ovarian cancer
Cytoreductive surgery (CRS) added with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the survival rate of certain patients with peritoneal metastasis (PM). However, the perioperative safety and long-term survival of this intricate and possibly life-threatening procedure in elderly patients (≥65 years) remain controversial.